Liquid Biopsies - The Clinics and the Molecules

J 2017

Liquid Biopsies - The Clinics and the Molecules

KUBACZKOVÁ, Veronika, Lenka SEDLAŘÍKOVÁ, Božena BOLLOVÁ, Viera SANDECKÁ, Martin ŠTORK et. al.

Basic information

Original name

Liquid Biopsies - The Clinics and the Molecules

Authors

KUBACZKOVÁ, Veronika (203 Czech Republic, belonging to the institution), Lenka SEDLAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Božena BOLLOVÁ (703 Slovakia, belonging to the institution), Viera SANDECKÁ (703 Slovakia), Martin ŠTORK (203 Czech Republic), Luděk POUR (203 Czech Republic) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Klinická onkologie, Praha, Ambit Media, 2017, 0862-495X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/17:00095663

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.14735/amko20172S13

Keywords in English

cell-free DNA non-coding RNA; liquid biopsies; minimal residual disease; multiple myeloma

Abstract

V originále

Unlike bone marrow bio psies, liquid bio psies represent a gentler, more accessible, less painful,repeatable and more comprehensive approach to get bio logically relevant information about the entire tumor but also about treatment response and level of minimal residual disease. This is all possible since peripheral blood contains not only circulating tumor cells but also many circulating molecules of nucleic acids (microRNA, cell-free DNA, long non-coding RNA etc.).Multiple myeloma is a genetically heterogeneous disease characterized by multifocal tumor deposits in the bone marrow but also focal lesions elsewhere. Single-site bio psy of the bone marrow creates a sampling bias that provides a limited molecular profile as the bio psy cannot capture all subclones. Moreover, during disease progression and treatment, molecular profile is changed and subclones of multiple myeloma cells resistant to treatment are formed. Likewise,various clones found in extramedullary sites that are not present in the bone marrow respond differently to treatment directly influencing survival of patients. Thus, liquid bio psies seem to be a relevant and necessary next step for diseases such as multiple myeloma.

Links

NV15-29508A, research and development project

Name: Cirkulující nukleové kyseliny jako markery progrese mnohočetného myelomu

Citovat

KUBACZKOVÁ, Veronika, Lenka SEDLAŘÍKOVÁ, Božena BOLLOVÁ, Viera SANDECKÁ, Martin ŠTORK, Luděk POUR and Sabina ŠEVČÍKOVÁ. Liquid Biopsies - The Clinics and the Molecules. Klinická onkologie. Praha: Ambit Media, 2017, vol. 30, Suppl. 2, p. "2S13"-"2S20", 8 pp. ISSN 0862-495X. Available from: https://dx.doi.org/10.14735/amko20172S13.

@article{1392121,
   author = {Kubaczková, Veronika and Sedlaříková, Lenka and Bollová, Božena and Sandecká, Viera and Štork, Martin and Pour, Luděk and Ševčíková, Sabina},
   article_location = {Praha},
   article_number = {Suppl. 2},
   doi = {http://dx.doi.org/10.14735/amko20172S13},
   keywords = {cell-free DNA non-coding RNA; liquid biopsies; minimal residual disease; multiple myeloma},
   language = {eng},
   issn = {0862-495X},
   journal = {Klinická onkologie},
   title = {Liquid Biopsies - The Clinics and the Molecules},
   volume = {30},
   year = {2017}
}

TY  - JOUR
ID  - 1392121
AU  - Kubaczková, Veronika - Sedlaříková, Lenka - Bollová, Božena - Sandecká, Viera - Štork, Martin - Pour, Luděk - Ševčíková, Sabina
PY  - 2017
TI  - Liquid Biopsies - The Clinics and the Molecules
JF  - Klinická onkologie
VL  - 30
IS  - Suppl. 2
SP  - "2S13"-"2S20"
EP  - "2S13"-"2S20"
PB  - Ambit Media
SN  - 0862495X
KW  - cell-free DNA non-coding RNA
KW  - liquid biopsies
KW  - minimal residual disease
KW  - multiple myeloma
N2  - Unlike bone marrow bio psies, liquid bio psies represent a gentler, more accessible, less painful,repeatable and more comprehensive approach to get bio logically relevant information about the entire tumor but also about treatment response and level of minimal residual disease. This is all possible since peripheral blood contains not only circulating tumor cells but also many circulating molecules of nucleic acids (microRNA, cell-free DNA, long non-coding RNA etc.).Multiple myeloma is a genetically heterogeneous disease characterized by multifocal tumor deposits in the bone marrow but also focal lesions elsewhere. Single-site bio psy of the bone marrow creates a sampling bias that provides a limited molecular profile as the bio psy cannot capture all subclones. Moreover, during disease progression and treatment, molecular profile is changed and subclones of multiple myeloma cells resistant to treatment are formed. Likewise,various clones found in extramedullary sites that are not present in the bone marrow respond differently to treatment directly influencing survival of patients. Thus, liquid bio psies seem to be a relevant and necessary next step for diseases such as multiple myeloma.
ER  -

KUBACZKOVÁ, Veronika, Lenka SEDLAŘÍKOVÁ, Božena BOLLOVÁ, Viera SANDECKÁ, Martin ŠTORK, Luděk POUR and Sabina ŠEVČÍKOVÁ. Liquid Biopsies - The Clinics and the Molecules. \textit{Klinická onkologie}. Praha: Ambit Media, 2017, vol.~30, Suppl. 2, p.~''2S13''-''2S20'', 8 pp. ISSN~0862-495X. Available from: https://dx.doi.org/10.14735/amko20172S13.

Detailed Information on Publication Record